ライフサイエンスコーパス: seminal vesicle

1 trol expression in liver, eye, intestine and seminal vesicle.

2 the ductal region and the ampulla of the rat seminal vesicle.

3 the incidence of cancer present only in the seminal vesicle.

4 ducts into the epididymis, vas deferens and seminal vesicle.

5 soybean, and cyclooxygenase (COX) from sheep seminal vesicle.

6 ecretory proteins produced by the guinea pig seminal vesicle.

7 ults in obstruction of the proximally placed seminal vesicle.

8 in 20 fractions in 5 weeks) to prostate and seminal vesicles.

9 omote prostate growth and antagonizes DHT in seminal vesicles.

10 eoplasia as well as hyperplasia/neoplasia in seminal vesicles.

11 dependent growth of the ventral prostate and seminal vesicles.

12 rone and precocious maturation of testis and seminal vesicles.

13 phogenesis defects in the prostate gland and seminal vesicles.

14 t ductal outgrowth in the prostate gland and seminal vesicles.

15 phogenesis and this was absent in svs mutant seminal vesicles.

16 oids while having no effect on the uterus or seminal vesicles.

17 ulting in an absence of mature sperms in the seminal vesicles.

18 ulbocavernosus (BC) muscle, scent gland, and seminal vesicles.

19 e fertility, accompanied by hypogonadism and seminal vesicle agenesis/hypodysplasia.

20 e weights) were observed in the prostate and seminal vesicles, along with minimal repression of circu

21 Therefore, we propose OSVIRA (Obstructed Seminal Vesicle and Ipsilateral Renal Agenesis) as an ac

22 ificity were low signal intensity within the seminal vesicle and lack of preservation of seminal vesi

23 on of Kgf mRNA during development of the rat seminal vesicle and prostate, both in vitro and in vivo.

24 mimic androgen action in explant cultures of seminal vesicle and prostate.

25 portant role in the development of the mouse seminal vesicle and rat ventral prostate.

26 tor of epithelial growth in the prostate and seminal vesicle and that the FGF10 gene is not regulated

27 or seminal actin-binding protein (SABP) from seminal vesicles and as extraparotid glycoprotein (EP-GP

28 rin was expressed in epithelial cells of the seminal vesicles and ejaculatory ducts.

29 The reverse is true in the seminal vesicles and fetal liver.

30 Furthermore, the involvement of seminal vesicles and other extracapsular extension were

31 Cultures from aorta, vas deferens, seminal vesicle, and kidney tissue were characterized wi

32 thelia of the adult mouse stomach, prostate, seminal vesicle, and the developing choroid plexus by in

33 dentified in amyloid deposits in the cornea, seminal vesicles, and brain.

34 ts; bilateral occlusion of the vas deferens, seminal vesicles, and ejaculatory ducts by calcification

35 l epithelial cells of human salivary glands, seminal vesicles, and the collecting tubules of the kidn

36 uantity of sperm released from the testes to seminal vesicles, and these tissues displayed rhythmic a

37 ntly lower, but not the weights of prostate, seminal vesicles, and uterus.

38 seminal vesicle and lack of preservation of seminal vesicle architecture.

39 For example, the testes and seminal vesicles are relatively large in species with hi

40 roductive system, including the prostate and seminal vesicles, are derived from epithelial precursors

41 ally all males exhibited enormously enlarged seminal vesicles because of pronounced hyperplasia of th

42 in uterus, lung, pancreas, salivary glands, seminal vesicles, bone marrow cells, and cecum, where it

43 and inhibition of ERK1/2 activation blocked seminal vesicle branching morphogenesis.

44 other mutations that reduce prostatic and/or seminal vesicle branching, the svs mutation dramatically

45 absent or atrophic, including the prostate, seminal vesicle, bulbourethral gland, and caudal ductus

46 gulated by androgen in both the prostate and seminal vesicles but not in other organs.

47 he development of prostate and possibly also seminal vesicle cancer.

48 Signal intensity in the peripheral zone and seminal vesicles decreased on T2-weighted images in 42 (

49 omized males without affecting the uterus or seminal vesicles, demonstrating that the classical genot

50 the BMP family, Gdf7, is required for normal seminal vesicle development.

51 ans in cases of microscopic transcapsular or seminal vesicle disease.

52 istal male reproductive tract (vas deferens, seminal vesicles, ejaculatory ducts).

53 ctivation also resulted in transformation of seminal vesicle epithelial cells in Pten-null mice.

54 from autologous benign prostatic epithelium, seminal vesicle epithelium, or fibroblasts.

55 ashion to control the differentiation of the seminal vesicle epithelium.

56 rowth, branching, and differentiation of the seminal vesicle epithelium.

57 Proteins expressed from the seminal vesicles evolve more rapidly than those from oth

58 bryos were transferred to females mated with seminal vesicle-excised males.

59 mi showed a reduction of spermatozoa and the seminal vesicles exhibited a dramatic reduction of semin

60 of prostatic glands, ejaculatory ducts, and seminal vesicles expressed E-cadherin but not N-cadherin

61 enetically marked Adh1 additionally promotes seminal vesicle expression suggesting downstream or intr

62 reoperative PSA, Gleason sum, stage, margin, seminal vesicle, extra-prostatic extension (EPE), HA, HY

63 -2 ligands in the seminal vesicle, we probed seminal vesicle fluid with 125I-labeled LRP-2 in a gel-b

64 h divergence in major protein composition of seminal vesicle fluid, suggesting that changes in gene e

65 nd to the prostasin-binding protein in mouse seminal vesicle fluid.

66 ly linked 82-kDa complex when incubated with seminal vesicle fluid.

67 ng protein was identified in mouse and human seminal vesicle fluid.

68 es such as the epididymis, vas deferens, and seminal vesicle from a straight Wolffian duct.

69 tion of fructose in human semen, a marker of seminal vesicle function.

70 of seminal fluid by surgical excision of the seminal vesicle gland.

71 n were associated with cancer involvement of seminal vesicles, higher Gleason sum, and a positive RT-

72 ous species, including bigger testes, larger seminal vesicles, higher sperm counts, richer mitochondr

73 (68)Ga-PSMA-11 localized in a lymph node and seminal vesicle in a patient with no abnormal (68)Ga-RM2

74 nd retrovesical in 17 (40%), within retained seminal vesicles in nine (22%), and at anterior or later

75 serum testosterone levels and enlargement of seminal vesicles in SIRT1 heterozygous males.

76 ess (HR, 1.7; 95% CI, 1.2-2.2; P =.001), and seminal vesicle invasion (HR, 1.4; 95% CI, 1.1-1.9; P =.

77 0001), positive surgical margins (P = .028), seminal vesicle invasion (P < .0001), lymph node involve

78 capsular extension (P <.01), and presence of seminal vesicle invasion (P <.01) were independent predi

79 ariate analysis, preoperative PSA (P = .04), seminal vesicle invasion (P = .02), PSA velocity (P < .0

80 extracapsular extension (all P < or = .005), seminal vesicle invasion (P = .07), and biochemical prog

81 /m(2)) had a significantly decreased risk of seminal vesicle invasion (P =.039).

82 ive margins, extracapsular extension, and no seminal vesicle invasion (P =.24).

83 level greater than 10 ng/mL (P: < or =.01), seminal vesicle invasion (P: =.02), prostatectomy Gleaso

84 in non-neoplastic prostates correlated with seminal vesicle invasion (rho = 0.275, P = 0.0169) and i

85 plasmic expression in tumors correlated with seminal vesicle invasion (rho = 0.282, P = 0.0098).

86 elation of extracapsular extension (ECE) and seminal vesicle invasion (SVI) was evaluated in 445 surg

87 traprostatic extension (EPE), 452 (18%) with seminal vesicle invasion (SVI), 1,434 (58%) with positiv

88 ikelihoods of extracapsular extension (ECE), seminal vesicle invasion (SVI), and adjacent organ invas

89 inimisation algorithm stratifying by risk of seminal vesicle invasion and centre to either the contro

90 xpression in prostate cancer cells decreased seminal vesicle invasion and distant metastases.

91 cantly correlated with human prostate cancer seminal vesicle invasion and lymph node metastasis.

92 rapy PSA level, surgical margins, PSADT, and seminal vesicle invasion are prognostic variables for a

93 es, and rates of extracapsular extension and seminal vesicle invasion compared with cancers not invol

94 leason score > or = 7, positive margins, and seminal vesicle invasion were associated with significan

95 tic extension, positive surgical margins, or seminal vesicle invasion) were randomly assigned to adju

96 ilaterally, with extracapsular extension, no seminal vesicle invasion, a 2-mm positive margin at the

97 ors such as the prostatectomy Gleason score, seminal vesicle invasion, absolute pre-RT PSA level, and

98 level, primary Gleason grade greater than 3, seminal vesicle invasion, and higher number of removed a

99 ports, the risks of extracapsular extension, seminal vesicle invasion, and lymph node metastasis were

100 c capsular invasion, surgical margin status, seminal vesicle invasion, and lymph node status.

101 iptional signature score was associated with seminal vesicle invasion, androgen-independent progressi

102 rgical margin, extraprostatic extension, and seminal vesicle invasion, as well as lymph node metastas

103 ed, along with 5 clinicopathologic features (seminal vesicle invasion, biopsy Gleason score, extracap

104 ositive margins, extraprostatic extension or seminal vesicle invasion, but interpretation of these an

105 , vascular invasion, lymph node involvement, seminal vesicle invasion, capsular penetration, positive

106 after radical prostatectomy include men with seminal vesicle invasion, Gleason score 8 to 10, extensi

107 ical margin status, extracapsular extension, seminal vesicle invasion, lymph node invasion, and andro

108 se pathologic findings at prostatectomy (ie, seminal vesicle invasion, positive surgical margins, ext

109 extracapsular extension, lymph node status, seminal vesicle invasion, post-radical retropubic prosta

110 ive prostate-specific antigen concentration, seminal vesicle invasion, surgical margin status, extrac

111 Gleason 4 or 5 patterns or extracapsular or seminal vesicle invasion.

112 05), transcapsular tumor spread (P < .0001), seminal vesicle involvement (P = .0012), and tumors of a

113 ), extraprostatic extension (P = 0.003), and seminal vesicle involvement (P = 0.002) at prostatectomy

114 with extracapsular extension (P = 0.044) and seminal vesicle involvement (P = 0.024).

115 ndom permuted blocks were used, with risk of seminal vesicle involvement and radiotherapy-treatment c

116 3aN0M0 prostate cancer, an estimated risk of seminal vesicle involvement less than 30%, prostate-spec

117 67.3%; isolated capsular penetration, 59.6%; seminal vesicle involvement, 79.6%; pelvic lymph node in

118 ed in patients with extracapsular extension, seminal vesicle involvement, higher prostatectomy Gleaso

119 ined disease, isolated capsular penetration, seminal vesicle involvement, or pelvic lymph node involv

120 logic features, such as a positive margin or seminal vesicle involvement, will develop biochemical fa

121 ifferentiated nonprostatic mouse epithelium (seminal vesicle) is sufficient for respecification to pr

122 specified for anatomic locations (prostate, seminal vesicles, local lymph nodes, distant lymph nodes

123 The prostate lobes, seminal vesicles, lungs, and periaortic lymph nodes were

124 examines the mechanism by which PHS from ram seminal vesicle microsomes catalyzes the oxidation of th

125 s, testes, and hormonal profile, and dilated seminal vesicles, midline cyst, or calcifications on TRU

126 Studies with pig prostate and seminal vesicle mitochondrial preparations also revealed

127 PET/CT correctly detected invasion of seminal vesicles (n = 11 of 21 patients; 52%) with 86% a

128 a more locally invasive phenotype and causes seminal vesicle obstruction at high penetrance.

129 ra (two cases, both with reflux) or into the seminal vesicle (one case); one case was contralateral a

130 or prostatectomy Gleason score of 8 to 10 or seminal vesicle or lymph node involvement.

131 n 4+3 tumours might overestimate the risk of seminal-vesicle or lymph-node invasion.

132 lesion, region (prostate, including bed and seminal vesicle, or extraprostatic, including all lymph

133 basal cell layer, stroma, ejaculatory ducts, seminal vesicles, or transitional epithelium.

134 -independent mechanism according to in vitro seminal vesicle organ cultures.

135 ated the development of ventral prostate and seminal vesicle organ rudiments in serum-free organ cult

136 yme activity in epididymis and low levels in seminal vesicle, ovary and uterus compared to other stra

137 sion of 76% for ventral prostate and 64% for seminal vesicle (P < 0.05 for both).

138 signal generated by reaction of purified ram seminal vesicle PGHS with arachidonic acid, suggesting t

139 ent in human tissues and highly expressed in seminal vesicles, pituitary, thyroid, pancreas, renal co

140 in the central tail artery, vasa deferentia, seminal vesicles, prostate, and uterus, with the latter

141 toxicity while inhibiting the development of seminal vesicle/prostate cancers in male rats by >50%.

142 pithelium were secretory proteins, including seminal vesicle protein secretion 2 and 5.

143 c autoantibodies against the human SVS2-like seminal vesicle protein semenogelin.

144 yocardium, adrenal cortex, epithelium of the seminal vesicles, proximal tubules and the collecting du

145 the GP1G gene was also active outside of the seminal vesicle, RNA from a variety of guinea pig tissue

146 immune responses to a prostate autoantigen, seminal vesicle secretory protein 2 (SVS2), which we bel

147 igh similarity to the coding exon of a human seminal vesicle secretory protein gene, semenogelin II.

148 ase gene and comparison with other mammalian seminal vesicle secretory protein genes reveals a common

149 t, the 100-kDa protein was identified as the seminal vesicle secretory protein II (SVS-II), a major c

150 These data suggest that these seminal vesicle secretory proteins may have functional r

151 nea pig codes for three of the four abundant seminal vesicle secretory proteins produced in this spec

152 The mouse seminal vesicle shape (svs) mutation is a spontaneous re

153 In the developing seminal vesicles, sustained activation of ERK1/2 was ass

154 ne is expressed at highest efficiency in the seminal vesicle (SV) from a promoter that contains a can

155 ilbestrol (DES) leads to feminization of the seminal vesicle (SV) in male mice, as illustrated by tis

156 ne production was assessed by measuring host seminal vesicle (SV) weights as an indirect measure over

157 lopment of the rat ventral prostate (VP) and seminal vesicle (SV).

158 Volumes of the prostate and seminal vesicles (SV) were calculated by using whole-vol

159 's AR agonist actions on the levator ani and seminal vesicle target tissues.

160 he capsule and low signal intensity within a seminal vesicle that has lost its normal architecture we

161 sia of the male genital tract, including the seminal vesicle, the vas deferens and the prostate.

162 HIP1R mRNA levels were decreased in seminal vesicle tissue from mice bearing miR-23b/-27b-tr

163 in 12 patients after needle puncture of the seminal vesicle to inject contrast material for radiogra

164 ) and coding region identical to that of the seminal vesicle transcript.

165 1 (11.2%) patients; obstructing cysts of the seminal vesicles, vas deferens, ejaculatory ducts, or pr

166 To identify LRP-2 ligands in the seminal vesicle, we probed seminal vesicle fluid with 12

167 es of activation, i.e. LH levels, testes and seminal vesicle weights were not altered.

168 nd 30 weeks of age, and prostate tissues and seminal vesicles were harvested.

169 nhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in seru